Investors

Corporate Profile

Cardiome is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.  Cardiome has two marketed, in-hospital, cardiology products, BrinavessTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and Aggrastat® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in Acute Coronary Syndrome patients.

Recent News

Corporate Presentations

Q2 2016 Conference Call - August 9, 2016

 

2016 AGM Materials